Table 2.

Activities of CIK cells from preclinical experiments to clinical studies.

In vitro cytotoxicity		Ref
Cell lines	B cell lymphoma SU-DHL	[8, 9]
	Multiple myeloma OPM-2,U266	[16, 26]
	T cell ALL CCRF-CEM-VBL (Vinblastine resistant)	[21]
	Erythroleukemia K562/Dox(Doxorubicin resistant)	[21]
Primary tumor cells	Acute myeloid leukemia	[11]
	Chronic myeloid leukemia	[22, 23]
	Chronic lymphocytic leukemia	[24, 25]
	Multiple myeloma	[26]
Mice studies
Cell lines	Human B cell lymphoma Su-DHL	[8, 9]
	Human cervical cancer HeLa	[30]
	Murine B cell lymphoma BCL1	[31, 32]
Primary tumor cells	Chronic myeloid leukemia	[22]
	Chronic lymphocytic leukemia	[24]
CIK cells administered with additional manipulation
With BsAb	CIK + BSAbxCA125 or BSAbxHER2 versus ovarian primary tumor and cell lines in vitro and in mice	[35]
	CIK + CD3xHER2/neu bsAb versus Ewing's family tumor cell lines in vitro and in mice	[36]
Gene transfection	IL-2 gene electroporated CIK + DC versus pancreatic tumor cell line Dan G	[28]
	Anti-CD19 chimeric receptor-redirected CIK versus ALL cell line REH and primary ALL cells	[37]
	Oncolytic virus transfected CIK versus human ovarian cell lines UCI-101 and SK-OV-3 in vitro and in mice	[38]
Clinical studies with demonstrated tumor response
Treatment: autologous	Follicular lymphoma (1 case)	[41]
	Hodgkin's disease (2 cases)	[42]
	Renal cell carcinoma (1 case)	[47]
Treatment: allogeneic	Myelodysplastic syndrome (1 case), Hodgkin's disease (1 case), Acute myeloid leukemia (1 case)	[49]
Clinical studies in adjuvant setting with demonstrated reduction in relapse
Autologous	Acute myelogenous and lymphoblastic leukemia	[44]
	Hepatocellular carcinoma (intra-arterial)	[46]